Ceribell

About Ceribell

Ceribell is a medical technology company specializing in the rapid detection and assessment of neonatal seizures in newborns. Operating at the intersection of neurology and neonatal care, Ceribell has developed innovative solutions to address critical gaps in early seizure detection, which is essential for improving outcomes in neonatal intensive care units (NICUs). Founded with a mission to enhance pediatric neurology, the company has established itself as a leader in providing timely diagnostic tools for healthcare professionals. The company’s flagship product, the Ceribell Rapid Neonatal Seizure Detection System, is a portable, non-invasive device that enables quick and accurate seizure detection at the bedside. Key features include real-time monitoring, automated analysis, and seamless integration with electronic health records, allowing clinicians to make informed decisions swiftly. Ceribell’s solutions are primarily targeted at neonatologists, pediatric neurologists, and NICU staff in hospitals and academic medical centers, where rapid intervention can significantly impact patient care. Ceribell has gained recognition for its transformative impact on neonatal care, with studies demonstrating its ability to reduce diagnostic delays and improve treatment initiation. The company holds a strong market position as a pioneer in rapid seizure detection technology, differentiating itself through its focus on speed, accuracy, and ease of use. By combining advanced neurotechnology with clinical expertise, Ceribell continues to advance the standard of care for newborns at risk of seizures.